Neuroscience & Medicine, 2013, 4, 299-318 299 Published Online December 2013 (http://www.scirp.org/journal/nm) http://dx.doi.org/10.4236/nm.2013.44044 Involvement of CRH Receptors in the Neuroprotective Action of R-Apomorphine in the Striatal 6-OHDA Rat Model Mustafa Varçin1, Eduard Bentea1, Steven Roosens1, Yvette Michotte1, Sophie Sarre1,2* 1Department of Pharmaceutical Chemistry and Drug Analysis, Center for Neurosciences, Vrije Universiteit Brussel, Faculty of Medicine and Pharmacy, Brussels, Belgium; 2Belgian Pharmacists Association, Medicines Control Laboratory, Brussels, Belgium. Email: *
[email protected] Received October 21st, 2013; revised November 20th, 2013; accepted December 10th, 2013 Copyright © 2013 Mustafa Varçin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT The dopamine D1-D2 receptor agonist, R-apomorphine, has been shown to be neuroprotective in different models of Parkinson’s disease. Different mechanisms of action for this effect have been proposed, but not verified in the striatal 6-hydroxydopamine rat model. In this study, the expression of a set of genes involved in 1) signaling, 2) growth and differentiation, 3) neuronal regeneration and survival, 4) apoptosis and 5) inflammation in the striatum was measured after a subchronic R-apomorphine treatment (10 mg/kg/day, subcutaneously, during 11 days) in the striatal 6-hydroxy- dopamine rat model. The expression of 84 genes was analysed by using the rat neurotrophins and receptors RT2 Pro- filer™ PCR array. The neuroprotective effects of R-apomorphine in the striatal 6-hydroxydopamine model were con- firmed by neurochemical and behavioural analysis.